E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Decreased Perihematomal Edema in Thrombolysis-Related Intracerebral Hemorrhage Compared With Spontaneous Intracerebral Hemorrhage
James Gebel,Thomas G. Brott,Cathy A. Sila,Thomas A. Tomsick,Edward C. Jauch,Shelia Salisbury,Jane Khoury,Rosemary Miller,Arthur M. Pancioli,John Duldner,Eric J. Topol,Joseph P. Broderick +11 more
TL;DR: The striking qualitative and quantitative lack of perihematomal edema observed in the thrombolysis-related ICHs compared with the SICHs provides the first substantial, although indirect, human evidence that intrahematomal blood clotting is a plausible pathogenetic factor in hyperacute perielectrical edema formation.
Journal ArticleDOI
Impact of Different Platelet Glycoprotein IIb/IIIa Receptor Inhibitors Among Diabetic Patients Undergoing Percutaneous Coronary Intervention Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-Year Follow-Up
Marco Roffi,David J. Moliterno,Bernhard Meier,Eric R. Powers,Cindy L. Grines,Peter M. DiBattiste,Howard C. Herrmann,Michel E. Bertrand,Katherine E. Harris,Laura A. Demopoulos,Eric J. Topol +10 more
TL;DR: It is suggested that the non-glycoprotein IIb/IIIa properties of abciximab do not translate into a discernible long-term clinical benefit among diabetic patients.
Journal ArticleDOI
Prediction of Causal Candidate Genes in Coronary Artery Disease Loci
Ingrid Braenne,Mete Civelek,Baiba Vilne,Antonio Fabio Di Narzo,Andrew D. Johnson,Yuqi Zhao,Benedikt Reiz,Veronica Codoni,Tom R. Webb,Hassan Foroughi Asl,Stephen E. Hamby,Lingyao Zeng,David-Alexandre Trégouët,Ke Hao,Eric J. Topol,Eric E. Schadt,Xia Yang,Nilesh J. Samani,Johan Björkegren,Jeanette Erdmann,Heribert Schunkert,Aldons J. Lusis +21 more
TL;DR: It is concluded that the great majority of causal variations affecting CAD risk occur in noncoding regions, with 41% affecting gene expression robustly versus 6% leading to amino acid changes.
Journal ArticleDOI
Late myocardial ischemic events after saphenous vein graft intervention--importance of initially "nonsignificant" vein graft lesions.
Stephen G. Ellis,Sorin J. Brener,Sue A DeLuca,E. Murat Tuzcu,Russell E. Raymond,Patrick L. Whitlow,Eric J. Topol +6 more
TL;DR: The low incidence of events from initially treated lesions < 50% suggests that the hypothesis that "nonsignificant" 41% to 50% lesions might best be treated at the time other more severe narrowings are treated should be examined, and a need for increased surveillance in patients with these lesions.
Journal ArticleDOI
Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: Improved timing, thrombolytic efficacy and ventricular function
Eric J. Topol,Eric R. Bates,Joseph A. Walton,Gregory Baumann,Stanley Wolfe,John Maino,Leonard Bayer,Laura Gorman,Eva M. Kline,William W. O'Neill,Bertram Pitt +10 more
TL;DR: As an investigational fibrinolytic agent for acute myocardial infarction, intravenous recombinant tissue-type plasminogen activator (rt-PA) has been administered primarily in tertiary care and university centers and the value of early initiation of such therapy was determined.